Novo Nordisk's patent on semaglutide, the active ingredient in Ozempic and Wegovy that reshaped the global weight-loss industry, expires in India on March 20. At least five Indian drugmakers are readying to sell cheaper copies of the drug. https://t.co/7X6Slgbiia ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its performance in securities class actions since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [4] - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [4]

Core Thesis - Eli Lilly and Company is positioned as a high-growth pharmaceutical leader, driven by the success of its tirzepatide franchise, which includes Mounjaro for diabetes and Zepbound for obesity [2][6] Financial Performance - Q4 revenue reached $19.3 billion, marking a 43% year-over-year increase, with reported EPS of $7.39 and non-GAAP EPS of $7.54 [3] - For the full year, revenue totaled $65.2 billion, representing a 45% growth, while reported net income nearly doubled to $20.6 billion [3] Product Performance - The growth was primarily volume-driven due to surging demand for tirzepatide, despite some pricing pressures [4] - Mounjaro generated $7.4 billion in Q4 revenue and $23.0 billion for the full year, while Zepbound achieved $4.3 billion in Q4 sales and $13.5 billion in its first full year, making it one of the fastest-growing drug launches in pharmaceutical history [4] Profitability and Investments - Eli Lilly maintained gross margins above 82% despite significant investments in manufacturing expansion, R&D, and commercial infrastructure [5] - R&D spending increased as the company advanced next-generation assets like oral GLP-1 candidate orforglipron and triple agonist retatrutide [5] Future Outlook - The company is expanding manufacturing capabilities with multi-billion-dollar facilities in the U.S. and Europe to meet long-term demand [6] - Management projects 2026 revenue between $80 billion and $83 billion and non-GAAP EPS of up to $35.00, indicating strong future growth potential [6]

Core Thesis - Merck & Co., Inc. is viewed positively by analysts, with a current share price of $117.11 and trailing and forward P/E ratios of 15.91 and 22.57 respectively [1] Financial Performance - In fiscal year 2025, Merck reported a fourth-quarter revenue of $16.4 billion, reflecting a 6% year-over-year increase, with GAAP EPS of $1.41 and non-GAAP EPS of $1.92, while maintaining gross margins around 77% [2] - For the full year, revenue increased by 8% to $64.2 billion, with GAAP EPS of $5.94 and non-GAAP EPS of $7.82, alongside approximately $23 billion in operating cash flow and about $19 billion in free cash flow [3] Revenue Drivers - Keytruda remains a significant growth driver, generating approximately $30.1 billion in revenue in 2025, up 10% year-over-year, supported by expanded indications and durable pricing power [4] - Vaccines contributed significantly, with Gardasil generating around $9.2 billion in revenue, driven by strong global demand [4] - The Animal Health segment produced roughly $6.0 billion in revenue, providing stable growth and diversification [4] Pipeline and Future Growth - The company is advancing its pipeline, with sotatercept showing promise for pulmonary arterial hypertension and potential multibillion-dollar revenue opportunities [5] - Additional oncology combination therapies and cardiometabolic and immunology assets are progressing towards Phase 3 readouts in 2026-2027, aimed at enhancing long-term growth prospects [5] Capital Allocation and Guidance - Merck maintained disciplined capital allocation, spending approximately $17 billion on R&D while focusing on bolt-on acquisitions and late-stage assets [6] - Management projects 2026 revenue between $63.5 billion and $65.5 billion, with non-GAAP EPS expected to be between $8.20 and $8.45, indicating confidence in near-term growth [6]

Core Insights - Evolus is experiencing signs of stabilization in the U.S. botulinum toxin market, while the recovery for dermal fillers is slower due to changing consumer sentiment [6][5] - The company has raised its long-term revenue targets for 2028, anticipating $450 million to $500 million, with adjusted EBITDA margins of 13% to 15% [15] Market Trends - The filler market is recovering slower than toxins, with negative sentiment around "overfilled" faces impacting hyaluronic acid (HA) fillers [2] - The company expects the market for toxins to return to mid-single-digit growth by 2027 and 2028, aligning with low-single-digit growth assumptions currently [3][5] Consumer Behavior - The 2024 downturn in the market is attributed to middle-class consumers reducing discretionary spending amid economic uncertainty, affecting all age groups and practice settings [4] - Consumers are stretching intervals between treatments to maximize the value of their spending [4] Product Launch and Technology - Evolus' new product, Evolysse, is gaining traction, currently available in about 3,000 U.S. clinics, and is expected to be a top HA launch despite broader category declines [8][12] - The technology behind Evolysse involves manufacturing HA gel at near-freezing temperatures to preserve its natural structure, leading to positive feedback from practitioners [8][9] Training and Adoption - The company has conducted hands-on training for over 12,000 injectors, with a second training session noted as a key factor in increasing product utilization [10] Strategic Initiatives - Evolus is bundling its products, Jeuveau and Evolysse, to enhance market share and compete more effectively against larger competitors [11][12] - The company has a consumer loyalty program with over 1.4 million participants, designed to encourage repeat visits to clinics [15] International Market Presence - Evolus has a direct presence in several European countries and Australia, with an estimated $2 billion opportunity in international markets for toxins and fillers [16] - The company expects international revenue to grow from 8% to about 15% of total revenue by 2028 [18]

Company Overview - EyePoint Pharmaceuticals is a biotechnology company focused on innovative sustained-release drug delivery systems for ocular diseases, particularly chronic and severe retinal conditions [5] - The company generates revenue primarily through product sales and strategic collaborations, with a product pipeline that includes ILUVIEN, YUTIQ, DEXYCU, and EYP-1901 [8] - EyePoint's main customers are healthcare providers and ophthalmologists treating retinal conditions in the United States, China, and the United Kingdom [8] Financial Performance - As of the latest report, EyePoint's market capitalization is $1.1 billion, with a revenue of $31.37 million for the trailing twelve months (TTM) [4] - The company reported a net income loss of approximately $231.96 million (TTM) as it continues to invest heavily in research and development [4][9] - EyePoint ended the year with about $306 million in cash and investments, sufficient to fund operations into late 2027 [9] Recent Developments - Parkman Healthcare Partners disclosed a new position in EyePoint, acquiring 1,088,033 shares in the fourth quarter, which increased the position's value by $19.88 million [2] - EyePoint shares have surged by 93% over the past year, significantly outperforming the S&P 500's 20% gain during the same period [7] - The company is advancing DURAVYU, a sustained-release therapy for serious retinal diseases, with Phase 3 trials currently enrolling over 900 patients and topline data expected in mid-2026 [7] Market Position - EyePoint is positioned to compete in a large ophthalmology market, which is currently dominated by frequent anti-VEGF injections [9] - The company’s differentiated product pipeline and strategic alliances support its leadership in ophthalmic therapeutics [5]

Group 1: Company Performance - Kenvue Inc. (NYSE:KVUE) is recognized as one of the top-performing consumer staples stocks in February [1] - Barclays has raised its price target for KVUE to $19 from $18 while maintaining an Equal Weight rating following updates to the company model after the Q4 report [1][8] Group 2: Legal Issues - A Texas judge rejected Kenvue's request to dismiss a lawsuit filed by the state's attorney general, which alleges that Kenvue misrepresented Tylenol by not disclosing potential hazards for children when pregnant women take the medication [2][3] - The ruling allows the case to proceed in Texas courts, highlighting ongoing scrutiny of drug labeling and public health protections for pregnant women and children [4] Group 3: Company Overview - Kenvue Inc. is a consumer health company that develops and markets personal care and wellness products, including leading brands in skin care, baby care, and over-the-counter health categories [5]

Group 1 - Eli Lilly and Company plans to invest $3 billion in China over the next decade to develop production capacity for its experimental type-2 diabetes and obesity treatment, orforglipron [1] - The company submitted a marketing application for orforglipron to China's drug regulator at the end of 2025 and aims to establish a localized manufacturing and supply system for oral solid dosage forms [1] - Eli Lilly is part of a trend among Western healthcare firms investing in manufacturing in China, following companies like Haleon, while others like Bristol Myers Squibb are divesting from the region [2] Group 2 - Eli Lilly develops, manufactures, discovers, and sells pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [3]

Core Insights - Viatris Inc. (NASDAQ:VTRS) is identified as one of the extreme value stocks to consider for investment, with a medium price target of $16, indicating a potential upside of 12.36% from current levels [1] - The company reported Q4 fiscal 2025 revenue of $3.7 billion, reflecting a 1% year-over-year growth when excluding the impact from the Indore facility [2] - Viatris generated $14.3 billion in total revenue for the full year 2025 and returned over $1 billion to shareholders during the year [2] - Free cash flow for the year reached $2.2 billion, excluding transaction-related costs, with management expecting earnings and revenue to improve in the second half of 2026 [3] - The company anticipates generating between $450 million and $550 million in revenue from new product launches in 2026 [3] Financial Performance - Q4 fiscal 2025 revenue was $3.7 billion, with a 1% year-over-year growth when excluding specific impacts [2] - Full-year revenue for 2025 totaled $14.3 billion, with over $1 billion returned to shareholders [2] - Free cash flow for the year was $2.2 billion, excluding transaction costs [3] Future Outlook - Management expects earnings and revenue to improve in the second half of 2026, supported by upcoming product launches and seasonality [3] - Forecasts indicate around 2% growth in both adjusted EBITDA and total revenue for 2026 [3] - Anticipated revenue from new product launches in 2026 is projected to be between $450 million and $550 million [3] Geographic Presence - Viatris operates in multiple regions including Japan, Europe, Hong Kong, Africa, North America, Australia, the Middle East, New Zealand, Taiwan, Latin America, China, and the rest of Asia [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for May 4, 2026 [2][4]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is publicly traded on NASDAQ under the ticker AQST [2]. - The company is currently facing legal scrutiny regarding its New Drug Application (NDA) for Anaphylm, which has been flagged by the FDA for deficiencies [5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Aquestive, alleging that the company and its executives made false or misleading statements and failed to disclose critical information regarding the NDA [4]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members, with the option for any member to move the court to serve as lead plaintiff [6]. Group 3: Stock Market Impact - Following the announcement of deficiencies in the NDA by the FDA, Aquestive's stock price dropped by $2.30, or 37.04%, closing at $3.91 per share on January 9, 2026 [5]. Group 4: Call for Information - Faruqi & Faruqi encourages individuals with information regarding Aquestive's conduct, including whistleblowers and former employees, to come forward [7].